Browsing Other ICR Research by author "Tutt, Andrew"
Now showing items 1-20 of 25
-
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt, ANJ; Garber, JE; Kaufman, B; Viale, G; Fumagalli, D; et al. (MASSACHUSETTS MEDICAL SOC, 2021-06-24)BACKGROUND: Poly(adenosine diphosphate-ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients with ... -
Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.
Yamauchi, H; Toi, M; Takayama, S; Nakamura, S; Takano, T; et al. (SPRINGER JAPAN KK, 2023-07-01)BACKGROUND: The efficacy and safety of olaparib compared with placebo in the subset of patients from Japan in the phase 3 OlympiA trial (NCT02032823) are reported here and contextualized with reference to the global OlympiA ... -
AllergoOncology: Expression platform development and functional profiling of an anti-HER2 IgE antibody.
Ilieva, KM; Fazekas-Singer, J; Bax, HJ; Crescioli, S; Montero-Morales, L; et al. (2019-10) -
Crosstalk between Innate Lymphoid Cells and Other Immune Cells in the Tumor Microenvironment.
Flores-Borja, F; Irshad, S; Gordon, P; Wong, F; Sheriff, I; et al. (HINDAWI LTD, 2016-01-01)Our knowledge and understanding of the tumor microenvironment (TME) have been recently expanded with the recognition of the important role of innate lymphoid cells (ILC). Three different groups of ILC have been described ... -
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Loibl, S; André, F; Bachelot, T; Barrios, CH; Bergh, J; et al. (Elsevier BV, 2023-12-08) -
Genomic Evolution of Breast Cancer Metastasis and Relapse.
Yates, LR; Knappskog, S; Wedge, D; Farmery, JHR; Gonzalez, S; et al. (CELL PRESS, 2017-08-14)Patterns of genomic evolution between primary and metastatic breast cancer have not been studied in large numbers, despite patients with metastatic breast cancer having dismal survival. We sequenced whole genomes or a panel ... -
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Davies, H; Glodzik, D; Morganella, S; Yates, LR; Staaf, J; et al. (NATURE PUBLISHING GROUP, 2017-04-01)Approximately 1-5% of breast cancers are attributed to inherited mutations in BRCA1 or BRCA2 and are selectively sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. In other cancer types, germline and/or somatic ... -
Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.
Tutt, A (OXFORD UNIV PRESS, 2018-01-01) -
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).
Tovey, H; Sipos, O; Parker, JS; Hoadley, KA; Quist, J; et al. (AMER ASSOC CANCER RESEARCH, 2023-09-15)PURPOSE: The TNT trial (NCT00532727) showed no evidence of carboplatin superiority over docetaxel in metastatic triple-negative breast cancer (mTNBC), but carboplatin benefit was observed in the germline BRCA1/2 mutation ... -
Integrin-Mediated Macrophage Adhesion Promotes Lymphovascular Dissemination in Breast Cancer.
Evans, R; Flores-Borja, F; Nassiri, S; Miranda, E; Lawler, K; et al. (CELL PRESS, 2019-05-14)Lymphatic vasculature is crucial for metastasis in triple-negative breast cancer (TNBC); however, cellular and molecular drivers controlling lymphovascular metastasis are poorly understood. We define a macrophage-dependent ... -
Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
Nik-Zainal, S; Davies, H; Staaf, J; Ramakrishna, M; Glodzik, D; et al. (NATURE PUBLISHING GROUP, 2016-06-02)We analysed whole-genome sequences of 560 breast cancers to advance understanding of the driver mutations conferring clonal advantage and the mutational processes generating somatic mutations. We found that 93 protein-coding ... -
Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
Denkert, C; Liedtke, C; Tutt, A; von Minckwitz, G (ELSEVIER SCIENCE INC, 2017-06-17)Triple-negative breast cancer is a heterogeneous disease and specific therapies have not been available for a long time. Therefore, conventional chemotherapy is still considered the clinical state of the art. Different ... -
New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.
Harvey-Jones, E; Vinas Villaro, G; Tutt, A (ASSOC DEVELOPPEMENT COMMUNICATION CANCEROLOGIQUE, 2021-11-01)Since the proof of concept of synthetic lethality between poly(ADP-ribose) polymerase inhibition and loss of BRCA1/2 homologous recombination (HR) function in preclinical models and early phase clinical trials, poly(ADP-ribose) ... -
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer, CE; Garber, JE; Gelber, RD; Yothers, G; Taboada, M; et al. (ELSEVIER, 2022-10-10)BACKGROUND: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or ... -
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
Telli, ML; Tolaney, SM; Shapiro, GI; Middleton, M; Lord, SR; et al. (NATURE PORTFOLIO, 2022-04-07)Platinum derivatives are commonly used for the treatment of patients with metastatic triple-negative breast cancer (TNBC). However, resistance often develops, leading to treatment failure. This expansion cohort (part C2) ... -
RORγt+ Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers.
Irshad, S; Flores-Borja, F; Lawler, K; Monypenny, J; Evans, R; et al. (AMER ASSOC CANCER RESEARCH, 2017-03-01)Cancer cells tend to metastasize first to tumor-draining lymph nodes, but the mechanisms mediating cancer cell invasion into the lymphatic vasculature remain little understood. Here, we show that in the human breast tumor ... -
Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypes.
Graham, R; Gazinska, P; Zhang, B; Khiabany, A; Sinha, S; et al. (FRONTIERS MEDIA SA, 2023-06-22)BACKGROUND: Intracellular communication within the tumour is complex and extracellular vesicles (EVs) have been identified as major contributing factors for the cell-to-cell communication in the local and distant tumour ... -
Somatic mutations reveal asymmetric cellular dynamics in the early human embryo.
Ju, YS; Martincorena, I; Gerstung, M; Petljak, M; Alexandrov, LB; et al. (NATURE PUBLISHING GROUP, 2017-03-30)Somatic cells acquire mutations throughout the course of an individual's life. Mutations occurring early in embryogenesis are often present in a substantial proportion of, but not all, cells in postnatal humans and thus ... -
Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survival.
Gracio, F; Burford, B; Gazinska, P; Mera, A; Mohd Noor, A; et al. (NATURE PORTFOLIO, 2017-01-06)Despite advancements in the use of transcriptional information to understand and classify breast cancers, the contribution of splicing to the establishment and progression of these tumours has only recently starting to ... -
Systemic Therapy for Hereditary Breast Cancers.
Harvey-Jones, EJ; Lord, CJ; Tutt, ANJ (W B SAUNDERS CO-ELSEVIER INC, 2023-02-01)Approximately 5% to 10% of all breast cancers are hereditary; many of which are caused by pathogenic variants in genes required for homologous recombination, including BRCA1 and BRCA2. Here we discuss systemic treatment ...